Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group
Pharmaceutical Research · 2023-07 · 40 (7) · 1601-1631
DOI: 10.1007/s11095-022-03391-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, online erschienen am 22.02.2023. Verfasst von Andrea Bauer und 20 weiteren Autor:innen. Beteiligte Einrichtung: Sunovion Pharmaceuticals, Marlborough, MA, 01752, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
Long-acting injectable (LAI) formulations can provide several advantages over the more traditional oral formulation as drug product opportunities. LAI formulations can achieve sustained drug release for extended periods of time, which results in less frequent dosing requirements leading to higher patient adherence and more optimal therapeutic outcomes. This review article will provide an industry perspective on the development and associated challenges of long-acting injectable formulations. The LAIs described herein include polymer-based formulations, oil-based formulations, and crystalline drug suspensions. The review discusses manufacturing processes, including quality controls, considerations of the Active Pharmaceutical Ingredient (API), biopharmaceutical properties and clinical requirements pertaining to LAI technology selection, and characterization of LAIs through in vitro, in vivo and in silico approaches. Lastly, the article includes a discussion around the current lack of suitable compendial and biorelevant in vitro models for the evaluation of LAIs and its subsequent impact on LAI product development and approval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sunovion Pharmaceuticals, Marlborough, MA, 01752, USA.
- UCB Pharma SA, Braine-l'Alleud, Belgium.
- Bristol Myers Squibb, New Brunswick, NJ, 08901, USA.
- GlaxoSmithKline, Collegeville, PA, 19426, USA.
- Eli Lilly and Company, Indianapolis, IN, USA.
- Biogen, Cambridge, MA, 02142, USA.
Zitieren
APA
Bauer, A., Berben, P., Chakravarthi, S. S., Chattorraj, S., Garg, A., Gourdon, B., Heimbach, T., Huang, Y., Morrison, C., Mundhra, D., Palaparthy, R., Saha, P., Siemons, M., Shaik, N. A., Shi, Y., Shum, S., Thakral, N. K., Urva, S., Vargo, R., …, & Barrett, S. E. (2023). Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group. Pharmaceutical Research, 40(7), 1601-1631. https://doi.org/10.1007/s11095-022-03391-y
Vancouver
Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, et al. Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group. Pharmaceutical Research. 2023;40(7):1601-1631. doi:10.1007/s11095-022-03391-y
BibTeX
@article{Bauer2023,
author = {Bauer, Andrea and Berben, Philippe and Chakravarthi, Sudhir S and Chattorraj, Sayantan and Garg, Ashish and Gourdon, Betty and Heimbach, Tycho and Huang, Ye and Morrison, Christopher and Mundhra, Deepak and Palaparthy, Ramesh and Saha, Pratik and Siemons, Maxime and Shaik, Naveed A and Shi, Yi and Shum, Sara and Thakral, Naveen K and Urva, Shweta and Vargo, Ryan and Koganti, Venkat R and Barrett, Stephanie E},
title = {Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group},
journal = {Pharmaceutical Research},
year = {2023},
volume = {40},
number = {7},
pages = {1601--1631},
doi = {10.1007/s11095-022-03391-y}
}
EUVIMED